Cara Therapeutics Garners $12,300,000 Series C Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=1304495a-224b-4dac-8464-58ea7cae3eaa&Preview=1 -
Date
7/25/2008 -
Company Name
Cara Therapeutics -
Mailing Address
One Parrott Drive Shelton, CT 06484 -
Company Description
Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. Cara’s first patented compound, CR665, has entered clinical testing for acute pain. This best-in-class compound possesses unique analgesic and anti-inflammatory activities appropriate for multiple therapeutic applications. In addition, Cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology. -
Website
http://www.caratherapeutics.com -
Transaction Type
Venture Equity -
Transaction Amount
$12,300,000 -
Transaction Round
Series C -
Proceeds Purposes
The additional funds will be used primarily for further clinical development of both intravenous and oral formulations of Cara’s second generation peripherally-selective kappa opioid agonist, CR845. -
M&A Terms
-
Venture Investor
Devon Park Bioventures -
Venture Investor
Ascent Venture Partners -
Venture Investor
Mitsubishi Corporation -
Venture Investor
Scottish Widows Investment Partnership -
Venture Investor
MVM Life Science Partners -
Venture Investor
Alta Partners
